Fibrinogen, a natural soluble blood protein, is at the heart of Fibriant’s science, technology and products. The conversion of Fibrinogen, by active Thrombin, into the insoluble Fibrin matrix is a pivotal step in hemostasis, tissue repair and host-defense against infections. In nature Fibrinogen and Fibrin appear in different forms, each form with a specific and unique structure-function profile. This variation in form and function provides Fibriant with many opportunities to create new and improved, customized healthcare solutions based on specific variants of human Fibrinogen and Fibrin. Fibriant has developed a recombinant manufacturing platform to produce different variants of human Fibrinogen as well as active human Thrombin.
Location: Netherlands, South Holland, Leiden
Employees: 1-10
Investors 1
Mentions in press and media 1
| Date | Title | Description |
| 22.12.2021 | Largest-ever funding round from EIC Accelerator: EC selects 99 startups to receive €627M; meet the 10 Dutch startups selected | The European Commission has announced the selection of 99 innovative startups and SMEs to be funded under the European Innovation Council (EIC) Accelerator programme. The selected startups will receive €627M of EU funding to help them bring... |